tetano
Editor, Senior Moderator
J Infect Dis. 2012 Dec 13. [Epub ahead of print]
A Cluster of Patients Infected with I221V Influenza B Virus Variants with Reduced Oseltamivir Susceptibility--North Carolina and South Carolina, 2010-2011.
Garg S, Moore Z, Lee N, McKenna J, Bishop A, Fleischauer A, Springs CB, Nguyen HT, Sheu TG, Sleeman K, Finelli L, Gubareva L, Fry AM.
Source
Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Abstract
Background. During 2010-2011, influenza B viruses with a novel neuraminidase substitution, denoted I221V, (B/I221V) associated with reduced in vitro oseltamivir susceptibility were detected in North Carolina (NC).Methods. We determined the prevalence of I221V among B viruses submitted to CDC for antiviral resistance surveillance, including all B viruses submitted to NC and South Carolina (SC) state laboratories, during October 2010-September 2011.We conducted chart reviews and phone interviews to characterize NC and SC patients with B/I221V versus wild-type B virus infection (B/WT).Results. We detected I221V in 45 (22%) of 209 B viruses from NC and 8 (10%) of 82 B viruses from SC. We detected I221V in three (0.3%) of 881 B viruses tested from 45 other states. B/I221V infection was not associated with differences in underlying conditions or illness severity compared with B/WT infection. No patients with B/I221V infection received oseltamivir prior to specimen collection. Among patients who completed oseltamivir, those with B/I221V infection reported a longer duration until illness resolution (5 versus 3 days); P=0.02.Conclusions. B/I221V co-circulated with B/WT in NC and SC during 2010-2011. I221V did not alter illness severity but may have reduced oseltamivir effectiveness. Thus, global surveillance for I221V is important.
PMID:
23242536
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/23242536
A Cluster of Patients Infected with I221V Influenza B Virus Variants with Reduced Oseltamivir Susceptibility--North Carolina and South Carolina, 2010-2011.
Garg S, Moore Z, Lee N, McKenna J, Bishop A, Fleischauer A, Springs CB, Nguyen HT, Sheu TG, Sleeman K, Finelli L, Gubareva L, Fry AM.
Source
Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Abstract
Background. During 2010-2011, influenza B viruses with a novel neuraminidase substitution, denoted I221V, (B/I221V) associated with reduced in vitro oseltamivir susceptibility were detected in North Carolina (NC).Methods. We determined the prevalence of I221V among B viruses submitted to CDC for antiviral resistance surveillance, including all B viruses submitted to NC and South Carolina (SC) state laboratories, during October 2010-September 2011.We conducted chart reviews and phone interviews to characterize NC and SC patients with B/I221V versus wild-type B virus infection (B/WT).Results. We detected I221V in 45 (22%) of 209 B viruses from NC and 8 (10%) of 82 B viruses from SC. We detected I221V in three (0.3%) of 881 B viruses tested from 45 other states. B/I221V infection was not associated with differences in underlying conditions or illness severity compared with B/WT infection. No patients with B/I221V infection received oseltamivir prior to specimen collection. Among patients who completed oseltamivir, those with B/I221V infection reported a longer duration until illness resolution (5 versus 3 days); P=0.02.Conclusions. B/I221V co-circulated with B/WT in NC and SC during 2010-2011. I221V did not alter illness severity but may have reduced oseltamivir effectiveness. Thus, global surveillance for I221V is important.
PMID:
23242536
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/23242536